Accordingly, EGFR amplification has been shown to be a negative prognostic factor for overall survival of glioblastoma patients and to correlate with shorter time to tumour progression (Schlegel et al, 1994a, 1994b; Zhu et al, 1996; Etienne et al, 1998). This evidence concerns the gene EGFR and neoplasm.